Celgene Corp. (CELG)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

86 MORRIS AVENUE SUMMIT, NJ 07901

Celgene is a biopharmaceutical company, engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. Co.'s commercial stage products include: REVLIMID, for the treatment in combination with dexamethasone for multiple myeloma patients; THALOMID, for the treatment of patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy for prevention of the cutaneous manifestation recurrence; and VIDAZA, that reverse the effects of deoxyribonucleic acid hypermethylation and promote gene re-expression.

Data as of 2019-12-02 09:46:21 -0500
Market Cap77.002 Billion Shares Outstanding711.4 Million Avg 30-day Volume
P/E Ratio Dividend Yield EPS8.34
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low110.7 / 58.59 Next Earnings Date Price to Cash FLow (P/CF)
Data provided by IEX Cloud
View SEC Filings from CELG instead.

View recent insider trading info

Funds Holding CELG (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CELG BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COX CARRIE SMITH

No longer subject to file 2019-11-20 0

MARIO ERNEST

No longer subject to file 2019-11-20 0

CASEY MICHAEL D

No longer subject to file 2019-11-20 0

WEILAND JOHN H

No longer subject to file 2019-11-20 0

BONNEY MICHAEL W

No longer subject to file 2019-11-20 0

BARKER RICHARD W

No longer subject to file 2019-11-20 0

LOUGHLIN JAMES J

No longer subject to file 2019-11-20 0

FRIEDMAN MICHAEL A

No longer subject to file 2019-11-20 0

ELKINS DAVID V EVP, CHIEF FINANCIAL OFFICER

No longer subject to file 2019-11-20 0

BISHOP HANS EDGAR

No longer subject to file 2019-11-20 0

HALL PATRICIA HEMINGWAY

No longer subject to file 2019-11-20 0

ALLES MARK J CEO, CHAIRMAN OF BOARD

No longer subject to file 2019-11-20 0

HALLER JULIA A

No longer subject to file 2019-11-20 0

VESSEY RUPERT PRES., RESEARCH AND EARLY DEV.

No longer subject to file 2019-11-20 0

CURRAN TERRIE PRES., GLBL INFLAM. AND IMMUN.

No longer subject to file 2019-11-20 0

AHMED NADIM PRES., GLOBAL HEM. AND ONC.

No longer subject to file 2019-11-20 0

BILLER JONATHAN EVP AND GENERAL COUNSEL

No longer subject to file 2019-11-20 0

REICIN ALISE PRES., GLOBAL CLINICAL DEV.

No longer subject to file 2019-11-20 0

KELLOGG PETER N SEE REMARKS

0 2018-07-30 0

MASOUDI GERALD SEE REMARKS

13,698 2018-06-01 0

KAPLAN GILLA

76,301 2018-05-18 0

SMITH SCOTT ANDREW SEE REMARKS

  • Officer
52,207 2018-02-17 0

HUGIN ROBERT J SEE REMARKS

  • Officer
  • Director
1,025,347 2017-12-31 0

PEHL MICHAEL F. SEE REMARKS

  • Officer
2,363 2017-07-28 0

FOUSE JACQUALYN A SEE REMARKS

  • Officer
  • Director
0 2017-02-14 0

KARSEN PERRY A SEE REMARKS

  • Officer
No longer subject to file 2015-12-31 0

DANIEL THOMAS O SEE REMARKS

  • Officer
No longer subject to file 2015-12-31 0

STEIN LAWRENCE V SEE REMARKS

  • Officer
14,568 2015-05-14 0

DRAKE RODMAN L

  • Director
26,180 2014-06-12 0

MORIARTY THOMAS M SEE REMARKS

  • Officer
0 2012-06-01 0

BURTON GRAHAM SEE REMARKS

  • Officer
0 2012-01-30 0

VAN HOEK ANDRE CONTROLLER AND CAO

  • Officer
0 2011-10-31 0

ROBB WALTER L

  • Director
No longer subject to file 2011-06-15 0

BARER SOL J

  • Director
753,473 2011-01-13 0

BROUWER AART SEE REMARKS

  • Officer
No longer subject to file 2010-12-31 0

GRYSKA DAVID W CHIEF FINANCIAL OFFICER

  • Officer
0 2010-07-13 0

HAYES ARTHUR H JR

  • Director
0 2010-02-09 0

MORGAN RICHARD C E

  • Director
116,732 2008-07-28 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments